CN112359146A - 一种用于快速检测乙型肝炎病毒基因的试剂盒及其检测方法 - Google Patents
一种用于快速检测乙型肝炎病毒基因的试剂盒及其检测方法 Download PDFInfo
- Publication number
- CN112359146A CN112359146A CN202011385303.1A CN202011385303A CN112359146A CN 112359146 A CN112359146 A CN 112359146A CN 202011385303 A CN202011385303 A CN 202011385303A CN 112359146 A CN112359146 A CN 112359146A
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- primer
- virus
- polymerase amplification
- recombinase polymerase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000700721 Hepatitis B virus Species 0.000 title claims abstract description 27
- 238000001514 detection method Methods 0.000 title claims abstract description 25
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 15
- 230000003321 amplification Effects 0.000 claims abstract description 18
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 18
- 102000018120 Recombinases Human genes 0.000 claims description 19
- 108010091086 Recombinases Proteins 0.000 claims description 19
- 239000013615 primer Substances 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108020001019 DNA Primers Proteins 0.000 claims description 5
- 239000003155 DNA primer Substances 0.000 claims description 5
- 108020005004 Guide RNA Proteins 0.000 claims description 5
- 108020004518 RNA Probes Proteins 0.000 claims description 5
- 239000003391 RNA probe Substances 0.000 claims description 5
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 claims description 4
- 239000011654 magnesium acetate Substances 0.000 claims description 4
- 229940069446 magnesium acetate Drugs 0.000 claims description 4
- 235000011285 magnesium acetate Nutrition 0.000 claims description 4
- 239000011541 reaction mixture Substances 0.000 claims description 4
- 238000012197 amplification kit Methods 0.000 claims description 3
- 239000007795 chemical reaction product Substances 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000013642 negative control Substances 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- 239000013641 positive control Substances 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims 1
- 230000005284 excitation Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 abstract description 5
- 102000039446 nucleic acids Human genes 0.000 abstract description 5
- 150000007523 nucleic acids Chemical class 0.000 abstract description 5
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 208000002672 hepatitis B Diseases 0.000 abstract description 4
- 230000035945 sensitivity Effects 0.000 abstract description 4
- 108091033409 CRISPR Proteins 0.000 abstract description 2
- 238000010354 CRISPR gene editing Methods 0.000 abstract description 2
- 208000035473 Communicable disease Diseases 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 abstract description 2
- 238000010362 genome editing Methods 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 108010014594 Heterogeneous Nuclear Ribonucleoprotein A1 Proteins 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 108020004638 Circular DNA Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000700739 Hepadnaviridae Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000700732 Orthohepadnavirus Species 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 1
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明属临床医学诊断领域,涉及乙型病毒性肝炎的诊断,以及感染病学、分子生物学和细胞生物学等领域。更具体地,本发明涉及血液中乙型肝炎病毒(Hepatitis B virus,HBV)基因的核酸扩增检测方法,提供了一种用于快速检测乙型肝炎病毒基因的试剂盒及其检测方法。本申请RPA与CRISPR/Cas13a的基因编辑系统相结合,可以便携、快速、精确地检测乙型肝炎病毒,具有很好的灵敏度和特异性。
Description
技术领域
本发明属临床医学诊断领域,涉及乙型病毒性肝炎的诊断,以及感染病学、分子生物学和细胞生物学等领域。更具体地,本发明涉及血液中乙型肝炎病毒(Hepatitis Bvirus,HBV)基因的核酸扩增检测方法,提供了一种用于快速检测乙型肝炎病毒基因的试剂盒及其检测方法。
背景技术
乙型肝炎是由乙型肝炎病毒(Hepatitis B virus,HBV)感染引起的以肝脏病变为主的一种传染病。临床上以肝功能损害、食欲减退、恶心、上腹部不适、肝区痛、乏力为主要表现,部分患者可有黄疸发热。部分乙肝患者可慢性化,甚至发展成肝硬化,少数可发展为肝癌。主要通过血和血制品、母婴传播及性接触传播。
HBV属嗜肝DNA病毒科(Hepadnaviridae)正嗜肝DNA病毒属(OrthoHepadnavirus)。HBV感染者血清中电镜下可见3种不同形态的颗粒。第一种为直径22nm的小球形空心颗粒,第二种为22nmx40-100nm的管状颗粒。这两种颗粒均为包膜成分,不含病毒的核酸。第三种为直径42nm的球形颗粒,称Dane颗粒,由包膜、核壳和核心组成。包膜由HBsAg组成;核壳由乙型肝炎核心抗原(HBcAg)组成;核心内有部分环状双链DNA和DNA聚合酶。
HBV基因组为部分环状双链DNA,由正链和负链组成,负链为长链。呈闭合型的环状DNA,全长约3200个核苷酸。正链为短链,呈半闭合型的环状DNA,全长为负链的50%-75%。
目前,常用HBV-DNA检测方法主要是荧光定量PCR法。荧光定量PCR法是一种集PCR技术、荧光信号检测和数据分析于一体的核酸定量检测技术。荧光定量PCR使用了特异性探针,能够对靶序列进行特异性的识别,具有引物探针双重控制,且综合了荧光标记技术、激光检测技术、数码显像技术,具有高特异性、高灵敏性,高准确性及低假阳性率等特点。其中热循环模块和荧光检测模块是荧光定量PCR不可缺少的组成部分,因此荧光定量PCR往往需要昂贵笨重的特殊仪器。这使得荧光定量PCR不适合在非实验室环境中使用。
重组酶聚合酶扩增技术(Recombinase polymerase amplification,RPA)技术是一种可应用于低温(37℃左右)的等温扩增技术,反应体系包括能结合单链核酸(寡核苷酸引物)的重组酶、具有链置换活性的DNA聚合酶、DNA单链结合蛋白(single strand DNA-binding protein,SSB)和Mg2+等,利用引物-重组酶复合物扫描DNA链,进而促进DNA链上对应同源位点的识别、结合、互换,通过DNA聚合酶和SSB共同作用合成互补新链,随着反应的进行,扩增产物以指数状态增长。RPA可作为一种便携、快速、性价比高的检测工具,实现实验室外的现场精确检测。
发明内容
本发明提供了一种灵敏度和特异性更强的检测乙型肝炎病毒的试剂盒及其检测方法。
本发明提供用于快速检测乙型肝炎病毒的引物,所述引物为重组酶聚合酶扩增DNA引物:
引物1-5′-GAAATTAATACGACTCACTATAGGGGCTGCTATGCCTCATCTTCTTGTTGGTTCTTCTG-3′
引物2-5′-TCCCGTGCTGGTTGTTGAGGATCCTGGAATTAGAG-3′。
所述引物用于制备快速检测乙型肝炎病毒的试剂盒的应用。
用于快速检测乙型肝炎病毒的试剂盒,包括:重组酶聚合酶扩增体系和Cas13反应体系;所述重组酶聚合酶扩增体系包括TwistAmp液态重组酶聚合酶扩增试剂盒和重组酶聚合酶扩增DNA引物:
引物1-5′-GAAATTAATACGACTCACTATAGGGGCTGCTATGCCTCATCTTCTTGTTGGTTCTT-CTG-3′
引物2-5′-TCCCGTGCTGGTTGTTGAGGATCCTGGAATTAGAG-3′
所述Cas13反应体系包括重组CRISPR-Cas13a蛋白、单链引导RNA和单链RNA探针。
单链引导RNA:
5′-ACUACCCCAAAAACGAAGGGGACUAAAACGACAAACGGGCAACAUACCUUGAUAGUC-3′
单链RNA探针:
5′-FAM-TUUUUUC-BHQ-1-3′。
具体的,
所述重组酶聚合酶扩增体系包括:
所述Cas13反应体系包括:
试剂盒检测乙型肝炎病毒基因的方法,包括如下步骤:
1)重组酶聚合酶扩增
(1)取HBV阳性对照稀释成3x105拷贝/μl,3x104拷贝/μl,3x103拷贝/μl,3x102拷贝/μl,3x10拷贝/μl,取1μl加入以下反应体系:
(2)加入1.25μl的20x核心反应混合液,混匀离心;
(3)加入1μl模板(不同稀释度的质粒模板和阴性对照);
(4)在管盖上加入1.25μl乙酸镁(MgOAc,280mM);
(5)颠倒混匀,离心后39度孵育20min。
2)用Cas13蛋白检测HBV
(1)取上述1ul反应产物加入Cas13反应体系,加入384孔透明圆底酶标板充分混合。设3个复孔:
(2)反应时间30min。
(3)检测:用多功能酶标仪检测仪,检测480nm激发光520nm发射波长的荧光强度。
本申请RPA与CRISPR/Cas13a的基因编辑系统相结合,可以便携、快速、精确地检测乙型肝炎病毒,具有很好的灵敏度和特异性。
附图说明
图1实施例1随时间荧光强度变化曲线。
图2实施例1加入模板浓度对荧光强度的影响。
具体实施方式
(一)材料
(1)重组酶聚合酶扩增DNA引物:
引物1-5′-GAAATTAATACGACTCACTATAGGGGCTGCTATGCCTCATCTTCTTGTTGGTTCTTCTG-3′
引物2-5′-TCCCGTGCTGGTTGTTGAGGATCCTGGAATTAGAG-3′
上述引物均于上海生工生物工程技术服务有限公司合成。
(2)单链引导RNA:
5′-ACUACCCCAAAAACGAAGGGGACUAAAACGACAAACGGGCAACAUACCUUGAUAGUC-3′,于上海生工生物工程技术服务有限公司合成。
(3)单链RNA探针:5′-FAM-TUUUUUC-BHQ-1-3′,
于上海生工生物工程技术服务有限公司合成。
(4)TwistAmp液态重组酶聚合酶扩增试剂盒,包含20x核心反应混合液、2倍反应缓冲液、280mM乙酸镁(MgOAc)、10x电子混合液,购于TwistDx公司。
(5)Trizma盐酸缓冲液-400mM Tris pH 7.4(Sigma Aldrich)。
(6)重组CRISPR-Cas13a蛋白,购于上海惠诚生物科技有限公司。
(7)RNase酶抑制剂,购于上海碧云天生物技术有限公司。
(8)NxGen T7RNA聚合酶,购于Lucigen公司。
(9)10mM NTP混合液,购于上海生工生物工程技术服务有限公司。
(10)氯化镁溶液(120mM),用六合氯化镁加ddH2O配成。
(二)方法:
1.重组酶聚合酶扩增
(1)取HBV阳性对照稀释成3x105拷贝/μl,3x104拷贝/μl,3x103拷贝/μl,3x102拷贝/μl,3x10拷贝/μl,取1μl加入以下反应体系:
(2)加入1.25μl的20x核心反应混合液,混匀离心;
(3)加入1μl模板(不同稀释度的质粒模板和阴性对照);
(4)在管盖上加入1.25μl乙酸镁(MgOAc,280mM);
(5)颠倒混匀,离心后39度孵育20min。
2.用Cas13蛋白检测HBV
(1)取上述1ul反应产物加入Cas13反应体系,加入384孔透明圆底酶标板充分混合。设3个复孔:
(2)反应时间30min。
(3)检测:用多功能酶标仪检测仪,检测480nm激发光520nm发射波长的荧光强度。
(三)结果
随着加入模板样本浓度的下降,孔内荧光强度逐渐下降,到30分钟时实验组相对于阴性组差异达到较为显著的程度(见图1)。重复进行实验共计3次,统计30分钟时各浓度梯度的荧光强度,可见样本浓度为30拷贝/μl时与对照组仍有明显差异。
序列表
<110> 浙江大学
<120> 一种用于快速检测乙型肝炎病毒基因的试剂盒及其检测方法
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 59
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 1
gaaattaata cgactcacta taggggctgc tatgcctcat cttcttgttg gttcttctg 59
<210> 2
<211> 35
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 2
tcccgtgctg gttgttgagg atcctggaat tagag 35
<210> 3
<211> 57
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 3
acuaccccaa aaacgaaggg gacuaaaacg acaaacgggc aacauaccuu gauaguc 57
<210> 4
<211> 6
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 4
uuuuuc 6
Claims (6)
1.用于快速检测乙型肝炎病毒的引物,所述引物为重组酶聚合酶扩增DNA引物:
引物1-5′-GAAATTAATACGACTCACTATAGGGGCTGCTATGCCTCATCTTCTTGTTGGTTCTTCTG-3′
引物2-5′-TCCCGTGCTGGTTGTTGAGGATCCTGGAATTAGAG-3′。
2.权利要求1所述引物用于制备快速检测乙型肝炎病毒的试剂盒的应用。
3.一种用于快速检测乙型肝炎病毒的试剂盒,包括:重组酶聚合酶扩增体系和Cas13反应体系;
所述重组酶聚合酶扩增体系包括TwistAmp液态重组酶聚合酶扩增试剂盒和重组酶聚合酶扩增DNA引物:
引物1-5′-GAAATTAATACGACTCACTATAGGGGCTGCTATGCCTCATCTTCTTGTTGGTTCTTCTG-3′
引物2-5′-TCCCGTGCTGGTTGTTGAGGATCCTGGAATTAGAG-3′
所述Cas13反应体系包括重组CRISPR-Cas13a蛋白、单链引导RNA和单链RNA探针
单链引导RNA:
5′-ACUACCCCAAAAACGAAGGGGACUAAAACGACAAACGGGCAACAUACCUUGAUAGUC-3′
单链RNA探针:
5′-FAM-TUUUUUC-BHQ-1-3′。
6.权利要求3-5任一所述试剂盒检测乙型肝炎病毒基因的方法,包括如下步骤:
1)重组酶聚合酶扩增
(1)取HBV阳性对照稀释成3x105拷贝/μl,3x104拷贝/μl,3x103拷贝/μl,3x102拷贝/μl,3x10拷贝/μl,取1μl加入以下反应体系:
(2)加入1.25μl的20x核心反应混合液,混匀离心;
(3)加入1μl模板(不同稀释度的质粒模板和阴性对照);
(4)在管盖上加入1.25μl乙酸镁(MgOAc,280mM);
(5)颠倒混匀,离心后39度孵育20min。
2)用Cas13蛋白检测HBV
(1)取上述1ul反应产物加入Cas13反应体系,加入384孔透明圆底酶标板充分混合;设3个复孔:
(2)反应时间30min;
(3)检测:用多功能酶标仪检测仪,检测480nm激发光520nm发射波长的荧光强度。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011385303.1A CN112359146A (zh) | 2020-11-30 | 2020-11-30 | 一种用于快速检测乙型肝炎病毒基因的试剂盒及其检测方法 |
PCT/CN2020/136280 WO2022110335A1 (zh) | 2020-11-30 | 2020-12-14 | 一种用于快速检测乙型肝炎病毒基因的试剂盒及其检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011385303.1A CN112359146A (zh) | 2020-11-30 | 2020-11-30 | 一种用于快速检测乙型肝炎病毒基因的试剂盒及其检测方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112359146A true CN112359146A (zh) | 2021-02-12 |
Family
ID=74535851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011385303.1A Pending CN112359146A (zh) | 2020-11-30 | 2020-11-30 | 一种用于快速检测乙型肝炎病毒基因的试剂盒及其检测方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN112359146A (zh) |
WO (1) | WO2022110335A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113150127A (zh) * | 2021-05-10 | 2021-07-23 | 北京保图生物技术有限公司 | 快速检测病毒的核酸抗体试剂盒 |
CN113684317A (zh) * | 2021-09-09 | 2021-11-23 | 贵州中医药大学第二附属医院 | 一种基于CRISPR-Cas12b对乙肝病毒B型和C型的超灵敏快速检测及鉴别系统 |
CN117402719A (zh) * | 2023-10-19 | 2024-01-16 | 上海交通大学医学院附属仁济医院 | 一种检测环状rna的方法及试剂盒 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200181720A1 (en) * | 2017-03-15 | 2020-06-11 | The Broad Institute, Inc. | Crispr effector system based diagnostics for virus detection |
WO2020124050A1 (en) * | 2018-12-13 | 2020-06-18 | The Broad Institute, Inc. | Tiled assays using crispr-cas based detection |
CN111593138A (zh) * | 2019-09-20 | 2020-08-28 | 山东省农业科学院家禽研究所 | 一种鸭乙型肝炎病毒重组聚合酶等温扩增检测方法 |
CN111748647A (zh) * | 2019-03-28 | 2020-10-09 | 中国医科大学 | 一种检测乙肝病毒的rpa引物、试剂、试剂盒及其应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100410268C (zh) * | 1998-12-23 | 2008-08-13 | 博伊斯汤普生植物研究所 | 免疫原性的乙型肝炎表面抗原在转基因植物中的表达 |
EP1399585B1 (en) * | 2000-10-23 | 2008-02-20 | Gen-Probe Incorporated | Compositions and methods for detecting human immunodeficiency virus 2 (hiv-2) |
KR20120044953A (ko) * | 2012-03-19 | 2012-05-08 | 주식회사 맥스바이오텍 | B형 간염 바이러스 진단을 위한 유전자 검사용 프라이머, 이의 검사 방법과 검사 키트 |
CN107604096B (zh) * | 2017-10-13 | 2019-09-03 | 杭州迪安医学检验中心有限公司 | 一种用于乙型肝炎病毒检测的核酸序列及试剂盒 |
CN109055499B (zh) * | 2018-08-30 | 2021-01-19 | 杭州杰毅生物技术有限公司 | 基于CRISPR-Cas的等温核酸检测方法及试剂盒 |
CN111041084A (zh) * | 2018-10-12 | 2020-04-21 | 中国科学院上海生命科学研究院 | 小胖威利综合征的检测试剂盒及其使用方法 |
CN110066865B (zh) * | 2019-04-30 | 2023-03-03 | 常州桐树生物科技有限公司 | 一种基于CRISPR-Cas13a的特异性核酸片段的检测方法及探针 |
CN110343785B (zh) * | 2019-08-05 | 2023-05-02 | 首都医科大学附属北京佑安医院 | 基于PCR-CRISPR-cas13a检测乙型肝炎病毒共价闭合环状DNA的试剂盒 |
CN111778288A (zh) * | 2020-07-17 | 2020-10-16 | 广州华腾生物医药科技有限公司 | 构建hbv转基因小鼠模型的方法、组合物和应用 |
-
2020
- 2020-11-30 CN CN202011385303.1A patent/CN112359146A/zh active Pending
- 2020-12-14 WO PCT/CN2020/136280 patent/WO2022110335A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200181720A1 (en) * | 2017-03-15 | 2020-06-11 | The Broad Institute, Inc. | Crispr effector system based diagnostics for virus detection |
WO2020124050A1 (en) * | 2018-12-13 | 2020-06-18 | The Broad Institute, Inc. | Tiled assays using crispr-cas based detection |
CN111748647A (zh) * | 2019-03-28 | 2020-10-09 | 中国医科大学 | 一种检测乙肝病毒的rpa引物、试剂、试剂盒及其应用 |
CN111593138A (zh) * | 2019-09-20 | 2020-08-28 | 山东省农业科学院家禽研究所 | 一种鸭乙型肝炎病毒重组聚合酶等温扩增检测方法 |
Non-Patent Citations (2)
Title |
---|
GOOTENBERG,JONATHAN S., ET AL: "Nucleic acid detection with CRISPR-Cas13a/C2c2", 《SCIENCE》 * |
王珊: "基于CRISPR技术的乙肝病毒DNA及YMDD耐药突变高灵敏检测技术研究", 《中国博士学位论文全文数据库(电子期刊)》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113150127A (zh) * | 2021-05-10 | 2021-07-23 | 北京保图生物技术有限公司 | 快速检测病毒的核酸抗体试剂盒 |
CN113684317A (zh) * | 2021-09-09 | 2021-11-23 | 贵州中医药大学第二附属医院 | 一种基于CRISPR-Cas12b对乙肝病毒B型和C型的超灵敏快速检测及鉴别系统 |
CN113684317B (zh) * | 2021-09-09 | 2023-09-26 | 贵州中医药大学第二附属医院 | 一种基于CRISPR-Cas12b对乙肝病毒B型和C型的超灵敏快速检测及鉴别系统 |
CN117402719A (zh) * | 2023-10-19 | 2024-01-16 | 上海交通大学医学院附属仁济医院 | 一种检测环状rna的方法及试剂盒 |
Also Published As
Publication number | Publication date |
---|---|
WO2022110335A1 (zh) | 2022-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kang et al. | Advances in nucleic acid amplification techniques (NAATs): COVID-19 point-of-care diagnostics as an example | |
Zhu et al. | PCR past, present and future | |
Li et al. | A comprehensive summary of a decade development of the recombinase polymerase amplification | |
CN112359146A (zh) | 一种用于快速检测乙型肝炎病毒基因的试剂盒及其检测方法 | |
Rajalakshmi | DIFFERENT TYPES OF PCR TECHNIQUES AND ITS APPLICATIONS. | |
CN102066573A (zh) | 用于扩增多个靶标的扩增子拯救多重聚合酶链式反应 | |
CN113801966B (zh) | 一种检测新型冠状病毒亚基因的荧光定量pcr方法及试剂盒 | |
CN112029900A (zh) | 新型冠状病毒的快速核酸检测方法及检测系统 | |
WO2023098157A1 (zh) | 用于hpv分型的多靶标核酸检测试剂盒和检测方法 | |
US20070281295A1 (en) | Detection of human papillomavirus E6 mRNA | |
JP2021000138A (ja) | 診断方法及び組成物 | |
Wang et al. | Graphene oxide and self-avoiding molecular recognition systems-assisted recombinase polymerase amplification coupled with lateral flow bioassay for nucleic acid detection | |
CN112725531B (zh) | 一种mcda结合生物传感器的乙肝病毒快速检测系统 | |
CN112029910B (zh) | SARS-CoV-2病毒核酸检测方法 | |
US20210147910A1 (en) | Hybrid multi-step nucleic acid amplification | |
Mu et al. | Microfluidic-based approaches for COVID-19 diagnosis | |
Gulinaizhaer et al. | Isothermal nucleic acid amplification technology in HIV detection | |
JPH09238687A (ja) | 核酸合成法 | |
Josko | Molecular virology in the clinical laboratory | |
CN114410836A (zh) | 一种集样本处理、核酸提取及多重恒温扩增一体化的检测人细小病毒b19的试剂盒和方法 | |
CN112501261B (zh) | 一种纳米等离子共振芯片增强等温扩增核酸荧光检测方法 | |
CN113215317A (zh) | 牛结节性皮肤病病毒野毒株的微滴数字pcr检测引物、探针、试剂盒及其应用 | |
CN106191317A (zh) | 一种基于数字pcr检测hpv16病毒的引物对及其试剂盒 | |
CN111575403A (zh) | 一种检测rna病毒核酸的高通量数字pcr试剂盒及检测方法 | |
JP2008154566A (ja) | E型肝炎ウイルスを検出するためのlamp増幅用核酸プライマーセット |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |